Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q2 2021 · 10-Q
Revenue—
Net Income-$10.39M-$10.39MN/M vs Q2 2020 EPS Diluted-$0.64-$0.64N/M vs Q2 2020 Operating Income-$10,445,000N/M Operating Cash Flowderived-$7,692,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,788,000N/M ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end